Therapeutic applications of antigen binding domain VHH derived from heavy chain antibodies of <i>Camelidae</i>
-
- Kishimoto Satoshi
- Graduate School of Science and Engineering, Kagoshima University
-
- Ito Yuji
- Graduate School of Science and Engineering, Kagoshima University
Bibliographic Information
- Other Title
-
- ラクダ科動物重鎖抗体由来の抗原結合ドメインVHHの医療技術への応用
Abstract
<p>VHH domain therapeutics derived from heavy chain antibodies of Camelidae are currently being developed as novel antibody therapeutics. Advantageous properties of this VHH include high stability, efficient bacterial expression, and ease of antibody engineering; however, it has a short blood half-life. Through examples from previous clinical studies, we would like to consider the issues and the prospects of the development of VHH therapeutics. Furthermore, we describe a new method of VHH development by combining a phage display library and high-throughput sequencing, and introduce the IgG-VHH conjugate as a novel antibody therapeutic prepared by antibody-specific modifications (CCAP: Chemical conjugation by affinity peptide).</p>
Journal
-
- MEDCHEM NEWS
-
MEDCHEM NEWS 27 (1), 35-41, 2017-02-01
The Pharmaceutical Society of Japan
- Tweet
Details 詳細情報について
-
- CRID
- 1390564238104840064
-
- NII Article ID
- 130007670655
-
- ISSN
- 24328626
- 24328618
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed